Announcements Trials
Browse Landscape

Phase

Phase 1 1

Status

Completed 1

Sponsor Class

INDUSTRY 1

Study Type

Interventional 1

Sponsor

Cancer Type

Gastrointestinal 1

Conditions

Pathologic Processes 1Pancreatic Neoplasms 1Neoplastic Processes 1Neoplasms by Site 1Neoplasms 1Neoplasm Metastasis 1Liver Neoplasms 1Liver Diseases 1Digestive System Neoplasms 1Digestive System Diseases 1

Interventions

Irinotecan 10Fluorouracil 10Leucovorin 9Bevacizumab 9Gemcitabine 8Paclitaxel 7Cisplatin 7Capecitabine 7Oxaliplatin 6130-nm albumin-bound paclitaxel 6Albumin-Bound Paclitaxel 5napabucasin 4Sorafenib 4Drug Therapy 4Cetuximab 4pembrolizumab 3apatinib 3Radiotherapy 3Ocoxin 3Imatinib Mesylate 3Folfox protocol 3Everolimus 3tislelizumab 2spartalizumab 2palbociclib 2entinostat 2encorafenib 2camrelizumab 2anlotinib 2Sunitinib 2

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Digestive System Neoplasms × ficlatuzumab × Gastrointestinal × Clear all
NCT00969410 2012-04-12

A Pharmacodynamic Study of AV-299 (Formerly SCH 900105) in Subjects With Advanced Solid Tumors Who Have Liver Metastases

AVEO Pharmaceuticals, Inc.

Phase 1 Completed
19 enrolled
Gastrointestinal

Digestive System Diseases, Digestive System Neoplasms, Liver Diseases, Liver Neoplasms, Neoplasm Metastasis, Neoplasms, Neoplasms by Site, Neoplastic Processes, Pathologic Processes

Data powered by HemOnc (CC BY 4.0) Colophon âš¡